Bienvenue dans la base de données-recherche

L'athérosclérose et ses complications cliniques

L'athérosclérose et ses complications cliniques, telles que la thrombose artérielle, l'ischémie et l'infarctus du myocarde, du cerveau et d'autres organes, continue de représenter la majorité de la morbidité et de la mortalité de la population adulte des pays industrialisés. L'athérosclérose est un processus progressif, multifactoriel débutant par l'accumulation dans la partie intimal de la paroi vasculaire de cellules inflammatoires de type lymphocytes et/ou macrophages, suivi par la prolifération et la migration de cellules musculaires lisses avec déposition de matrice extra-cellulaires. Ce processus atteint l'aorte, les artères carotidiennes, coronaires, iliaques et fémorales. Les facteurs de risque cardio-vasculaires tels que le tabagisme, le diabète, l'hypertension artérielle, l'obésité, et l'hyperlipidémie induisent une dysfonction endothéliale qui contribue précocement aux mécanismes de l¿athérogenèse. Cependant, puisque ces facteurs de risque affectent tout le système vasculaire, il ne peuvent à eux seuls expliquer l'atteinte focale de l'athérosclérose. Au contraire, les forces hémodynamiques imposées à la paroi vasculaire artérielle par le flux sanguin pulsatile varie localement en fonction de la géométrie et de l'architecture du vaisseau, et sont de ce fait un bon candidat pour expliquer le processus focale lié au développement de l'athérosclérose. En effet, plusieurs études récentes ont démontrés que l'athérosclérose se développait de façon préférentielle dans des zones de flux sanguin lent et turbulent, et presque jamais aux endroits où ce flux et rapide ou laminaire. Il semble donc évident que les forces hémodynamiques vasculaires participent de manière importante au développement de l'athérosclérose.
La présence et l'accumulation de cellules immuno-inflammatoire, de type lymphocytes et macrophages, dans les lésions d'athérosclérose est bien documentée, mais les différents processus qui permettent le recrutement de ces cellules inflammatoires de la circulation vers la paroi vasculaires sont encore obscures et très mal compris.
Dans plusieurs de recherche, nous proposons de déterminer à l'aide d'un modèle unique ex vivo d'athérosclérose l'expression et l'implication de molécules, telles que les cytokines, les chémokines, les molécules d'adhésions, dans la dysfonction endothéliale et le recrutement de cellules inflammatoires lors des premières étapes de l'athérogenèse. Nous proposons d'examiner et de déterminer le rôle des différents facteurs de risque, y compris les forces hémodynamiques, ainsi que de certains traitement (anti-diabétique, hypolipémiant) lors de ces processus initiant l'athérosclérose. Ces recherches devraient nous permettre de mieux comprendre les différents processus inflammatoires liés à l'athérogenèse, ainsi que le bénéfice de certains traitement.

Publications du groupe

HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial.
AIDS
2009 vol. 23(8) pp. 929-939
CALMY A AND AL.

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.
AMERICAN HEART JOURNAL
2009 vol. 158(6) pp. 896-901
SCHWARTZ GG AND AL.

Statins, ACE inhibitors and ARBs in cardiovascular disease.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
2009 vol. 23(3) pp. 389-400
MONTECUCCO F, MACH F

Percutaneous retrieval of intravascular and intracardiac foreign bodies with a dedicated three-dimensional snare: a 3-year single center experience.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS : OFFICIAL JOURNAL OF THE SOCIETY FOR CARDIAC ANGIOGRAPHY & INTERVENTIONS
2009 vol. 74(6) pp. 939-945
BONVINI R, RASTAN A, SIXT S, NOORY E, BESCHORNER U, LEPPANEN O, MACH F, SCHWARZWÄLDER U, BÜRGELIN K, ZELLER T

Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
CIRCULATION
2009 vol. 120(22) pp. 2188-2196
MCMURRAY J AND AL.

Chlorhexidine prevents hypochlorous acid-induced inactivation of alpha1-antitrypsin.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
2009 vol. 36(11) pp. 72-77
MONTECUCCO F, BERTOLOTTO M, OTTONELLO L, PENDE A, DAPINO P, QUERCIOLI A, MACH F, DALLEGRI F

Acute coronary syndrome and its antithrombotic treatment: focus on aspirin and clopidogrel resistance.
CURRENT VASCULAR PHARMACOLOGY
2009 vol. 7(2) pp. 198-208
BONVINI R, RENY JL, MACH F, ZELLER T, FONTANA P

Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome.
DIABETES, OBESITY AND METABOLISM
2009 vol. 11(5) pp. 445-454
MONTECUCCO F, MACH F

Stair use for cardiovascular disease prevention.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION
2009 vol. 16 pp. 17-18
MEYER P, KAYSER B, MACH F

Ezetimibe/simvastatin.
EXPERT OPINION ON DRUG SAFETY
2009 vol. 8(6) pp. 715-725
MONTECUCCO F, QUERCIOLI A, MACH F

Swimming prevents vulnerable atherosclerotic plaque development in hypertensive 2-kidney, 1-clip mice by modulating angiotensin II type 1 receptor expression independently from hemodynamic changes.
HYPERTENSION
2009 vol. 53(5) pp. 782-789
PELLEGRIN M AND AL.

Oxaprozin-induced apoptosis on CD40 ligand-treated human primary monocytes is associated with the modulation of defined intracellular pathways.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
2009 vol. 2009 pp. 478785-
MONTECUCCO F, BERTOLOTTO M, OTTONELLO L, QUERCIOLI A, MACH F, DALLEGRI F

Noninvasive stress testing of myocardial perfusion defects: head-to-head comparison of thallium-201 SPECT to MRI perfusion.
JOURNAL OF NUCLEAR CARDIOLOGY : OFFICIAL PUBLICATION OF THE AMERICAN SOCIETY OF NUCLEAR CARDIOLOGY
2009 vol. 16(4) pp. 549-561
VINCENTI G, NKOULOU R, STEINER C, IMPERIANO H, AMBROSIO G, MACH F, RATIB O, VALLEE JP, SCHINDLER TH

The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies.
MEDIATORS OF INFLAMMATION
2009 vol. 2009 pp. 752406-752406
MONTECUCCO F, PENDE A, MACH F

Early versus delayed, provisional eptifibatide in acute coronary syndromes.
NEW ENGLAND JOURNAL OF MEDICINE
2009 vol. 360(21) pp. 2176-21790
GIUGLIANO R AND AL.

Obstructive sleep apnea and atherosclerosis.
PROGRESS IN CARDIOVASCULAR DISEASES
2009 vol. 51(5) pp. 400-410
LEVY P, PEPIN JL, ARNAUD C, BAGUET JP, DEMATEIS M, MACH F

Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis.
RHEUMATOLOGY : OFFICIAL JOURNAL OF THE BRITISH SOCIETY FOR RHEUMATOLOGY
2009 vol. 48(1) pp. 11-22
MONTECUCCO F, MACH F

Atherosclerosis is an inflammatory disease.
SEMINARS IN IMMUNOPATHOLOGY
2009 vol. 31(1) pp. 1-3
MONTECUCCO F, MACH F

Update on statin-mediated anti-inflammatory activities in atherosclerosis.
SEMINARS IN IMMUNOPATHOLOGY
2009 vol. 31(1) pp. 127-142
MONTECUCCO F, MACH F

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.
AMERICAN HEART JOURNAL
2008 vol. 156(5) pp. 826-832
CANNON CP AND AL.

CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways.Am J Physiol Heart Circ Physiol
AMERICAN JOURNAL OF PHYSIOLOGY. HEART AND CIRCULATORY PHYSIOLOGY
2008 vol. 294(3) pp. 1145-1155
MONTECUCCO F, BURGER F, MACH F, STEFFENS S

A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice.
ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY
2008 vol. 28(6) pp. 1090-1096
BRAUNERSREUTHER V, STEFFENS S, ARNAUD C, PELLI G, BURGER F, PROUDFOOT A, MACH F

Cannabinoid receptors in acute and chronic complications of atherosclerosis.
BRITISH JOURNAL OF PHARMACOLOGY
2008 vol. 153(2) pp. 290-298
MACH F, MONTECUCCO F, STEFFENS S

PARP1 is required for adhesion molecule expression in atherogenesis.
CARDIOVASCULAR RESEARCH
2008 vol. 78(1) pp. 158-166
VON LUKOWICZ T AND AL.

Tumor necrosis factor-alpha (TNF-alpha) induces integrin CD11b/CD18 (Mac-1) up-regulation and migration to the CC chemokine CCL3 (MIP-1alpha) on human neutrophils through defined signalling pathways.
CELLULAR SIGNALLING
2008 vol. 20(3) pp. 557-568
MONTECUCCO F, STEFFENS S, BURGER F, DA COSTA A, BIANCHI G, BERTOLOTTO M, MACH F, DALLEGRI F, OTTONELLO L

Adiponectin and adaptive immunity: linking the bridge from obesity to atherogenesis.
CIRCULATION RESEARCH
2008 vol. 102(2) pp. 140-142
STEFFENS S, MACH F

Anti-apolipoprotein A-1 IgG are associated with high oxidized low-density lipoprotein levels of in acute coronary syndrome
CLINICAL SCIENCE
2008 vol. 115(1) pp. 25-33
VUILLEUMIER NICOLAS ET AL.

A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy.
HUMAN MUTATION
2008 vol. 29(6) pp. 879-885
FOKSTUEN S AND AL

C-reactive protein (CRP) induces chemokine secretion via CD11b/ICAM-1 interaction in human adherent monocytes.
JOURNAL OF LEUKOCYTE BIOLOGY
2008 vol. 84(4) pp. 1109-1119
MONTECUCCO F, STEFFENS S, BURGER F, PELLI G, MONACO C, MACH F

Renin-angiotensin system blockade and contrast-induced renal toxicity.
JOURNAL OF NEPHROLOGY
2008 vol. 21(5) pp. 681-685
SAUDAN P, MULLER H, FERAILLE E, MARTIN PY, MACH F

The role of the endocannabinoid system in atherosclerosis.
JOURNAL OF NEUROENDOCRINOLOGY
2008 vol. 20 pp. 53-57
MACH F, STEFFENS S

Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability.
MEDIATORS OF INFLAMMATION
2008 vol. 2008 pp. 767623-767623
MONTECUCCO F, STEFFENS S, MACH F

Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness.
THROMBOSIS RESEARCH
2008 vol. 121(4) pp. 463-468
FONTANA P, SENOUF DAVID, MACH F

Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
2007 vol. 27 pp. 373-379
BRAUNERSREUTHER V, ZERNECKE A, ARNAUD C, LIEHN EA, STEFFENS S, SHAGDARSUREN E, BIDZHEKOV K, BURGER F, PELLI G, LUCKOW B, MACH F, WEBER C

The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability?
CLINICAL & DEVELOPMENTAL IMMUNOLOGY
2007 vol. 2007 pp. 75805-
MONTECUCCO F, STEFFENS S, MACH F

Atorvastatin treatment and vaccination efficacy.
JOURNAL OF CLINICAL PHARMACOLOGY.
2007 vol. 47(8) pp. 1022-1027
PACKARD RR, SCHLEGEL S, SENOUF DAVID, BURGER F, SIGAUD P, PERNEGER T, SIEGRIST CA, MACH F

Diagnostic value of PET-measured heterogeneity in myocardial blood flows during cold pressor testing for the identification of coronary vasomotor dysfunction.
JOURNAL OF NUCLEAR CARDIOLOGY : OFFICIAL PUBLICATION OF THE AMERICAN SOCIETY OF NUCLEAR CARDIOLOGY
2007 vol. 14(5) pp. 688-697
SCHINDLER TH, ZHANG XL, VINCENTI G, MHIRI L, NKOULOU R, JUST H, RATIB O, MACH F, DAHLBOM M, SCHELBERT HR

Rosuvastatin in older patients with systolic heart failure
NEW ENGLAND JOURNAL OF MEDICINE
2007 vol. 357 pp. 2248-2261
KJEKSHUS J, APETREI E, BARRIOS V, BOHM M, CLELAND JGF, CORNEL JH, DUNSELMAN P, FONSECA C, GOUDEV A, GRANDE P, GULLESTAD L, HJALMARSON A, HRADEC J, JANOSI A, KAMENSKY G, KOMAJDA M, KOREWICKI J, KUUSI T, MACH F, MAREEV V, MCMURRAY JJV

Heart rate as a cardiovascular risk factor: potential clinical benefit with ivabradine
REVUE MÉDICALE SUISSE
2007 vol. 3(113) pp. 1375-1382
PURCELL H, MACH F

Immunization of LDL receptor-deficient mice with beta(2)-glycoprotein 1 or human serum albumin induces a more inflammatory phenotype in atherosclerotic plaques
THROMBOSIS AND HAEMOSTASIS
2007 vol. 97 pp. 129-138
DUNOYER-GEINDRE S, KWAK BR, PELLI G, ROTH I, SATTA N, FISH RJ, REBER G, MACH F, KRUITHOF EKO, DE MOERLOOSE P

The specific role of chemokines in atherosclerosis
THROMBOSIS AND HAEMOSTASIS
2007 vol. 97 pp. 714-721
BRAUNERSREUTHER V, MACH F, STEFFENS S

New anti-inflammatory agents to reduce atherosclerosis.
ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
2006 vol. 112(2) pp. 130-137
MACH F

Potential antiinflammatory and immunomodulatory effects of statins in rheumatologic therapy
ARTHRITIS AND RHEUMATISM --
2006 vol. 54 pp. 390-392
ARNAUD C, MACH F

Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages
ATHEROSCLEROSIS
2006 vol. 188 pp. 51-58
VEILLARD NR, BRAUNERSREUTHER V, ARNAUD C, BURGER F, PELLI G, STEFFENS S, MACH F

Leukocyte recruitment in atherosclerosis: Potential targets for therapeutic approaches?
CELLULAR AND MOLECULAR LIFE SCIENCES
2006 vol. 63 pp. 2079-2088
BRAUNERSREUTHER V, MACH F

Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice
CIRCULATION
2006 vol. 114 pp. 1977-1984
STEFFENS S, BURGER F, PELLI G, DEAN Y, ELSON G, KOSCO-VILBOIS M, CHATENOUD L, MACH F

Cannabinoid receptors in atherosclerosis
CURRENT OPINION IN LIPIDOLOGY
2006 vol. 17(5) pp. 519-526
STEFFENS S, MACH F

Drug insight: Immunomodulatory effects of statins--potential benefits for renal patients?
NATURE CLINICAL PRACTICE NEPHROLOGY
2006 vol. 2(7) pp. 378-387
STEFFENS S, MACH F

La dysfonction érectile un possible marqueur de maladies cardiovalculaires
REVUE MÉDICALE SUISSE
2006 vol. 2(58) pp. 774-778
SEKORANJA L, BIANCHI-DEMICHELI F, GASPOZ JM, MACH F

Soluble CD40 ligand in prediction of acute severe pancreatitis
WORLD JOURNAL OF GASTROENTEROLOGY
2006 vol. 12 pp. 1613-1616
FROSSARD JL, MOREL P, KWAK BR, PASTOR CM, BERNEY T, BUHLER L, VON LAUFEN A, DEMULDER S, MACH F

Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice
CIRCULATION RESEARCH
2004 vol. 94 pp. 253-261
VEILLARD NIELS, KWAK CHANSON BRENDA, PELLI GRAZIANO, MULHAUPT FLORE, JAMES RICHARD, PROUDFOOT A, MACH FRANCOIS

Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
CARDIOVASCULAR RESEARCH
2003 vol. 59 pp. 755-766
MULHAUPT F, MATTER CM, KWAK BR, PELLI G, VEILLARD NR, BURGER F, GRABER P, LUSCHER TF, MACH F

Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice
CIRCULATION
2003 vol. 107 pp. 1033-1039
KWAK BR, VEILLARD N, PELLI G, MULHAUPT F, JAMES RW, CHANSON M, MACH F

PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class II induction in atheroma-associated cells
CIRCULATION RESEARCH
2002 vol. 90 pp. 356-362
KWAK BR, MYIT S, MULHAUPT F, VEILLARD NR, RUFER N, ROOSNEK E, MACH F

Statins as a newly recognized type of immunomodulator
NATURE. MEDICINE
2000 vol. 6 pp. 1399-1402
KWAK CHANSON BRENDA, MULHAUPT FLORE, MYIT SAMIR, MACH FRANCOIS

Domaines de recherche




BASE DE DONNÉES-RECHERCHE	GROUPE DE RECHERCHE CLINIQUE ORIENTEE PATIENTS

François MACH	CV du Chef de Groupe	Sujet de Recherche	Composition du Groupe


	Coordonnées du groupe Prof. François MACH Fondation Recherche Médicales 64 Avenue Roseraie 1211 Genève Suisse François.mach@unige.ch Tél.: + 41 22 382 72 34 Fax: + 41 22 382 72 45 Commentaires Pages générées le 17.11.2015		Sujet de recherche \| Publications du groupe \| Domaines de recherche L'athérosclérose et ses complications cliniques L'athérosclérose et ses complications cliniques, telles que la thrombose artérielle, l'ischémie et l'infarctus du myocarde, du cerveau et d'autres organes, continue de représenter la majorité de la morbidité et de la mortalité de la population adulte des pays industrialisés. L'athérosclérose est un processus progressif, multifactoriel débutant par l'accumulation dans la partie intimal de la paroi vasculaire de cellules inflammatoires de type lymphocytes et/ou macrophages, suivi par la prolifération et la migration de cellules musculaires lisses avec déposition de matrice extra-cellulaires. Ce processus atteint l'aorte, les artères carotidiennes, coronaires, iliaques et fémorales. Les facteurs de risque cardio-vasculaires tels que le tabagisme, le diabète, l'hypertension artérielle, l'obésité, et l'hyperlipidémie induisent une dysfonction endothéliale qui contribue précocement aux mécanismes de l¿athérogenèse. Cependant, puisque ces facteurs de risque affectent tout le système vasculaire, il ne peuvent à eux seuls expliquer l'atteinte focale de l'athérosclérose. Au contraire, les forces hémodynamiques imposées à la paroi vasculaire artérielle par le flux sanguin pulsatile varie localement en fonction de la géométrie et de l'architecture du vaisseau, et sont de ce fait un bon candidat pour expliquer le processus focale lié au développement de l'athérosclérose. En effet, plusieurs études récentes ont démontrés que l'athérosclérose se développait de façon préférentielle dans des zones de flux sanguin lent et turbulent, et presque jamais aux endroits où ce flux et rapide ou laminaire. Il semble donc évident que les forces hémodynamiques vasculaires participent de manière importante au développement de l'athérosclérose. La présence et l'accumulation de cellules immuno-inflammatoire, de type lymphocytes et macrophages, dans les lésions d'athérosclérose est bien documentée, mais les différents processus qui permettent le recrutement de ces cellules inflammatoires de la circulation vers la paroi vasculaires sont encore obscures et très mal compris. Dans plusieurs de recherche, nous proposons de déterminer à l'aide d'un modèle unique ex vivo d'athérosclérose l'expression et l'implication de molécules, telles que les cytokines, les chémokines, les molécules d'adhésions, dans la dysfonction endothéliale et le recrutement de cellules inflammatoires lors des premières étapes de l'athérogenèse. Nous proposons d'examiner et de déterminer le rôle des différents facteurs de risque, y compris les forces hémodynamiques, ainsi que de certains traitement (anti-diabétique, hypolipémiant) lors de ces processus initiant l'athérosclérose. Ces recherches devraient nous permettre de mieux comprendre les différents processus inflammatoires liés à l'athérogenèse, ainsi que le bénéfice de certains traitement. Publications du groupe HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009 vol. 23(8) pp. 929-939 CALMY A AND AL. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. AMERICAN HEART JOURNAL 2009 vol. 158(6) pp. 896-901 SCHWARTZ GG AND AL. Statins, ACE inhibitors and ARBs in cardiovascular disease. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM 2009 vol. 23(3) pp. 389-400 MONTECUCCO F, MACH F Percutaneous retrieval of intravascular and intracardiac foreign bodies with a dedicated three-dimensional snare: a 3-year single center experience. CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS : OFFICIAL JOURNAL OF THE SOCIETY FOR CARDIAC ANGIOGRAPHY & INTERVENTIONS 2009 vol. 74(6) pp. 939-945 BONVINI R, RASTAN A, SIXT S, NOORY E, BESCHORNER U, LEPPANEN O, MACH F, SCHWARZWÄLDER U, BÜRGELIN K, ZELLER T Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. CIRCULATION 2009 vol. 120(22) pp. 2188-2196 MCMURRAY J AND AL. Chlorhexidine prevents hypochlorous acid-induced inactivation of alpha1-antitrypsin. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY 2009 vol. 36(11) pp. 72-77 MONTECUCCO F, BERTOLOTTO M, OTTONELLO L, PENDE A, DAPINO P, QUERCIOLI A, MACH F, DALLEGRI F Acute coronary syndrome and its antithrombotic treatment: focus on aspirin and clopidogrel resistance. CURRENT VASCULAR PHARMACOLOGY 2009 vol. 7(2) pp. 198-208 BONVINI R, RENY JL, MACH F, ZELLER T, FONTANA P Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome. DIABETES, OBESITY AND METABOLISM 2009 vol. 11(5) pp. 445-454 MONTECUCCO F, MACH F Stair use for cardiovascular disease prevention. EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION 2009 vol. 16 pp. 17-18 MEYER P, KAYSER B, MACH F Ezetimibe/simvastatin. EXPERT OPINION ON DRUG SAFETY 2009 vol. 8(6) pp. 715-725 MONTECUCCO F, QUERCIOLI A, MACH F Swimming prevents vulnerable atherosclerotic plaque development in hypertensive 2-kidney, 1-clip mice by modulating angiotensin II type 1 receptor expression independently from hemodynamic changes. HYPERTENSION 2009 vol. 53(5) pp. 782-789 PELLEGRIN M AND AL. Oxaprozin-induced apoptosis on CD40 ligand-treated human primary monocytes is associated with the modulation of defined intracellular pathways. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY 2009 vol. 2009 pp. 478785- MONTECUCCO F, BERTOLOTTO M, OTTONELLO L, QUERCIOLI A, MACH F, DALLEGRI F Noninvasive stress testing of myocardial perfusion defects: head-to-head comparison of thallium-201 SPECT to MRI perfusion. JOURNAL OF NUCLEAR CARDIOLOGY : OFFICIAL PUBLICATION OF THE AMERICAN SOCIETY OF NUCLEAR CARDIOLOGY 2009 vol. 16(4) pp. 549-561 VINCENTI G, NKOULOU R, STEINER C, IMPERIANO H, AMBROSIO G, MACH F, RATIB O, VALLEE JP, SCHINDLER TH The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. MEDIATORS OF INFLAMMATION 2009 vol. 2009 pp. 752406-752406 MONTECUCCO F, PENDE A, MACH F Early versus delayed, provisional eptifibatide in acute coronary syndromes. NEW ENGLAND JOURNAL OF MEDICINE 2009 vol. 360(21) pp. 2176-21790 GIUGLIANO R AND AL. Obstructive sleep apnea and atherosclerosis. PROGRESS IN CARDIOVASCULAR DISEASES 2009 vol. 51(5) pp. 400-410 LEVY P, PEPIN JL, ARNAUD C, BAGUET JP, DEMATEIS M, MACH F Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. RHEUMATOLOGY : OFFICIAL JOURNAL OF THE BRITISH SOCIETY FOR RHEUMATOLOGY 2009 vol. 48(1) pp. 11-22 MONTECUCCO F, MACH F Atherosclerosis is an inflammatory disease. SEMINARS IN IMMUNOPATHOLOGY 2009 vol. 31(1) pp. 1-3 MONTECUCCO F, MACH F Update on statin-mediated anti-inflammatory activities in atherosclerosis. SEMINARS IN IMMUNOPATHOLOGY 2009 vol. 31(1) pp. 127-142 MONTECUCCO F, MACH F Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. AMERICAN HEART JOURNAL 2008 vol. 156(5) pp. 826-832 CANNON CP AND AL. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways.Am J Physiol Heart Circ Physiol AMERICAN JOURNAL OF PHYSIOLOGY. HEART AND CIRCULATORY PHYSIOLOGY 2008 vol. 294(3) pp. 1145-1155 MONTECUCCO F, BURGER F, MACH F, STEFFENS S A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY 2008 vol. 28(6) pp. 1090-1096 BRAUNERSREUTHER V, STEFFENS S, ARNAUD C, PELLI G, BURGER F, PROUDFOOT A, MACH F Cannabinoid receptors in acute and chronic complications of atherosclerosis. BRITISH JOURNAL OF PHARMACOLOGY 2008 vol. 153(2) pp. 290-298 MACH F, MONTECUCCO F, STEFFENS S PARP1 is required for adhesion molecule expression in atherogenesis. CARDIOVASCULAR RESEARCH 2008 vol. 78(1) pp. 158-166 VON LUKOWICZ T AND AL. Tumor necrosis factor-alpha (TNF-alpha) induces integrin CD11b/CD18 (Mac-1) up-regulation and migration to the CC chemokine CCL3 (MIP-1alpha) on human neutrophils through defined signalling pathways. CELLULAR SIGNALLING 2008 vol. 20(3) pp. 557-568 MONTECUCCO F, STEFFENS S, BURGER F, DA COSTA A, BIANCHI G, BERTOLOTTO M, MACH F, DALLEGRI F, OTTONELLO L Adiponectin and adaptive immunity: linking the bridge from obesity to atherogenesis. CIRCULATION RESEARCH 2008 vol. 102(2) pp. 140-142 STEFFENS S, MACH F Anti-apolipoprotein A-1 IgG are associated with high oxidized low-density lipoprotein levels of in acute coronary syndrome CLINICAL SCIENCE 2008 vol. 115(1) pp. 25-33 VUILLEUMIER NICOLAS ET AL. A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. HUMAN MUTATION 2008 vol. 29(6) pp. 879-885 FOKSTUEN S AND AL C-reactive protein (CRP) induces chemokine secretion via CD11b/ICAM-1 interaction in human adherent monocytes. JOURNAL OF LEUKOCYTE BIOLOGY 2008 vol. 84(4) pp. 1109-1119 MONTECUCCO F, STEFFENS S, BURGER F, PELLI G, MONACO C, MACH F Renin-angiotensin system blockade and contrast-induced renal toxicity. JOURNAL OF NEPHROLOGY 2008 vol. 21(5) pp. 681-685 SAUDAN P, MULLER H, FERAILLE E, MARTIN PY, MACH F The role of the endocannabinoid system in atherosclerosis. JOURNAL OF NEUROENDOCRINOLOGY 2008 vol. 20 pp. 53-57 MACH F, STEFFENS S Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. MEDIATORS OF INFLAMMATION 2008 vol. 2008 pp. 767623-767623 MONTECUCCO F, STEFFENS S, MACH F Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. THROMBOSIS RESEARCH 2008 vol. 121(4) pp. 463-468 FONTANA P, SENOUF DAVID, MACH F Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 2007 vol. 27 pp. 373-379 BRAUNERSREUTHER V, ZERNECKE A, ARNAUD C, LIEHN EA, STEFFENS S, SHAGDARSUREN E, BIDZHEKOV K, BURGER F, PELLI G, LUCKOW B, MACH F, WEBER C The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? CLINICAL & DEVELOPMENTAL IMMUNOLOGY 2007 vol. 2007 pp. 75805- MONTECUCCO F, STEFFENS S, MACH F Atorvastatin treatment and vaccination efficacy. JOURNAL OF CLINICAL PHARMACOLOGY. 2007 vol. 47(8) pp. 1022-1027 PACKARD RR, SCHLEGEL S, SENOUF DAVID, BURGER F, SIGAUD P, PERNEGER T, SIEGRIST CA, MACH F Diagnostic value of PET-measured heterogeneity in myocardial blood flows during cold pressor testing for the identification of coronary vasomotor dysfunction. JOURNAL OF NUCLEAR CARDIOLOGY : OFFICIAL PUBLICATION OF THE AMERICAN SOCIETY OF NUCLEAR CARDIOLOGY 2007 vol. 14(5) pp. 688-697 SCHINDLER TH, ZHANG XL, VINCENTI G, MHIRI L, NKOULOU R, JUST H, RATIB O, MACH F, DAHLBOM M, SCHELBERT HR Rosuvastatin in older patients with systolic heart failure NEW ENGLAND JOURNAL OF MEDICINE 2007 vol. 357 pp. 2248-2261 KJEKSHUS J, APETREI E, BARRIOS V, BOHM M, CLELAND JGF, CORNEL JH, DUNSELMAN P, FONSECA C, GOUDEV A, GRANDE P, GULLESTAD L, HJALMARSON A, HRADEC J, JANOSI A, KAMENSKY G, KOMAJDA M, KOREWICKI J, KUUSI T, MACH F, MAREEV V, MCMURRAY JJV Heart rate as a cardiovascular risk factor: potential clinical benefit with ivabradine REVUE MÉDICALE SUISSE 2007 vol. 3(113) pp. 1375-1382 PURCELL H, MACH F Immunization of LDL receptor-deficient mice with beta(2)-glycoprotein 1 or human serum albumin induces a more inflammatory phenotype in atherosclerotic plaques THROMBOSIS AND HAEMOSTASIS 2007 vol. 97 pp. 129-138 DUNOYER-GEINDRE S, KWAK BR, PELLI G, ROTH I, SATTA N, FISH RJ, REBER G, MACH F, KRUITHOF EKO, DE MOERLOOSE P The specific role of chemokines in atherosclerosis THROMBOSIS AND HAEMOSTASIS 2007 vol. 97 pp. 714-721 BRAUNERSREUTHER V, MACH F, STEFFENS S New anti-inflammatory agents to reduce atherosclerosis. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY 2006 vol. 112(2) pp. 130-137 MACH F Potential antiinflammatory and immunomodulatory effects of statins in rheumatologic therapy ARTHRITIS AND RHEUMATISM -- 2006 vol. 54 pp. 390-392 ARNAUD C, MACH F Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages ATHEROSCLEROSIS 2006 vol. 188 pp. 51-58 VEILLARD NR, BRAUNERSREUTHER V, ARNAUD C, BURGER F, PELLI G, STEFFENS S, MACH F Leukocyte recruitment in atherosclerosis: Potential targets for therapeutic approaches? CELLULAR AND MOLECULAR LIFE SCIENCES 2006 vol. 63 pp. 2079-2088 BRAUNERSREUTHER V, MACH F Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice CIRCULATION 2006 vol. 114 pp. 1977-1984 STEFFENS S, BURGER F, PELLI G, DEAN Y, ELSON G, KOSCO-VILBOIS M, CHATENOUD L, MACH F Cannabinoid receptors in atherosclerosis CURRENT OPINION IN LIPIDOLOGY 2006 vol. 17(5) pp. 519-526 STEFFENS S, MACH F Drug insight: Immunomodulatory effects of statins--potential benefits for renal patients? NATURE CLINICAL PRACTICE NEPHROLOGY 2006 vol. 2(7) pp. 378-387 STEFFENS S, MACH F La dysfonction érectile un possible marqueur de maladies cardiovalculaires REVUE MÉDICALE SUISSE 2006 vol. 2(58) pp. 774-778 SEKORANJA L, BIANCHI-DEMICHELI F, GASPOZ JM, MACH F Soluble CD40 ligand in prediction of acute severe pancreatitis WORLD JOURNAL OF GASTROENTEROLOGY 2006 vol. 12 pp. 1613-1616 FROSSARD JL, MOREL P, KWAK BR, PASTOR CM, BERNEY T, BUHLER L, VON LAUFEN A, DEMULDER S, MACH F Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice CIRCULATION RESEARCH 2004 vol. 94 pp. 253-261 VEILLARD NIELS, KWAK CHANSON BRENDA, PELLI GRAZIANO, MULHAUPT FLORE, JAMES RICHARD, PROUDFOOT A, MACH FRANCOIS Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. CARDIOVASCULAR RESEARCH 2003 vol. 59 pp. 755-766 MULHAUPT F, MATTER CM, KWAK BR, PELLI G, VEILLARD NR, BURGER F, GRABER P, LUSCHER TF, MACH F Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice CIRCULATION 2003 vol. 107 pp. 1033-1039 KWAK BR, VEILLARD N, PELLI G, MULHAUPT F, JAMES RW, CHANSON M, MACH F PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class II induction in atheroma-associated cells CIRCULATION RESEARCH 2002 vol. 90 pp. 356-362 KWAK BR, MYIT S, MULHAUPT F, VEILLARD NR, RUFER N, ROOSNEK E, MACH F Statins as a newly recognized type of immunomodulator NATURE. MEDICINE 2000 vol. 6 pp. 1399-1402 KWAK CHANSON BRENDA, MULHAUPT FLORE, MYIT SAMIR, MACH FRANCOIS Domaines de recherche